FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ON	1R	AP	PR	Ω	/A

OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Amato Anthony N.		2. Date of Event Requiring Statement (Month/Day/Year) 04/30/2024	3. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]					
(Last)	(First) (Middle)			Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date of Original Filed (Month/Day/Year)	
C/O BIOSIG T	ECHNOLOGIES ARMS RD	, INC.		X	Officer (give title below) Chief Executive (10% Owner Other (specify below)	Individual or Joint/Group Filing (Check Applicable Line) Y Form filed by One Reporting Person	
(Street) WESTPORT	CT	06880			Chief Executive	Officer	Form filed by More than One Reporting Person	
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	l '
Common Stock, \$0.001 par value per share	500,000(1)	D	
Common Stock, \$0.001 par value per share	50,000(2)	D	
Common Stock, \$0.001 par value per share	6,250(3)	D	
Common Stock, \$0.001 par value per share	1,952(4)	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of Derivative Security (Instr. 4)			Perivative Security (Instr. 4)		Conversion or Exercise	sion Form: Direct cise (D) or	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	erivative (Instr. 5)		

Explanation of Responses:

- 1. The shares of restricted stock were granted for services and were fully vested as of March 1, 2024, the date of the grant, based on a closing price of \$0.705 per share.
- 2. The shares of restricted stock were granted for services and were fully vested as of June 7, 2024, the date of the grant, based on a closing price of \$1.865 per share.
- 3. Consists of (i) 2,500 shares of restricted stock granted for services on January 5, 2021 with a cost basis of \$39,90 that vested in equal quarterly installments over one year, and (ii) 3,750 shares of restricted stock units granted for services on June 26, 2023 with an average cost basis of \$5.05 that vested in two equal quarterly installments.
- 4. The shares of common stock were purchased in a private placement on March 12, 2019, based on a price of \$40.00 per share.

Remarks:

 $Mr.\ Amato\ was\ appointed\ as\ chief\ executive\ of Ficer\ of\ BioSig\ Technologies,\ Inc.\ on\ April\ 30,\ 2024.$

<u>/s/ Anthony Amato</u> <u>07/05/2024</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.